Ductal carcinoma-in-situ: long-term results of breast-conserving therapy
The role of breast-conserving therapy (BCT) in the management of ductal carcinoma-in-situ (DCIS) is controversial because of reported high recurrence rates. We reviewed our experience to determine whether the rate and pattern of locoregional recurrence after BCT were similar in patients with DCIS an...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2000-10, Vol.7 (9), p.656-664 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 664 |
|---|---|
| container_issue | 9 |
| container_start_page | 656 |
| container_title | Annals of surgical oncology |
| container_volume | 7 |
| creator | Mirza, N Q Vlastos, G Meric, F Sahin, A A Singletary, S E Newman, L A Kuerer, H M Ames, F C Ross, M I Feig, B W Pollock, R E Buchholz, T A McNeese, M D Strom, E A Hortobagyi, G N Hunt, K K |
| description | The role of breast-conserving therapy (BCT) in the management of ductal carcinoma-in-situ (DCIS) is controversial because of reported high recurrence rates. We reviewed our experience to determine whether the rate and pattern of locoregional recurrence after BCT were similar in patients with DCIS and patients with early-stage (T1) invasive breast tumors and whether local recurrence affected survival.
Between 1973 and 1994, 87 patients with DCIS alone, 22 patients with DCIS with microinvasion (DCIS-M), and 646 patients with invasive breast cancer 2 cm or smaller in diameter were treated with BCT (wide local excision with radiotherapy) at The University of Texas M. D. Anderson Cancer Center. Survival was calculated by the Kaplan-Meier method. The median follow-up times were 11 years for patients with DCIS alone, 12 years for patients with DCIS-M, and 8 years for patients with invasive breast cancer.
Eleven (13%) of 87 patients with DCIS and 5 (23%) of 22 patients with DCIS-M had developed locoregional recurrences at follow-up. Two patients with DCIS with locoregional recurrence died of breast cancer. Of the 646 patients with invasive breast cancer, 56 (9%) had a locoregional recurrence, and 16 (2%) died of breast cancer. The median time to locoregional recurrence was significantly longer in patients with DCIS or DCIS-M (9-10 years) than patients with invasive tumors (5 years).
DCIS is a favorable disease with an excellent long-term survival. The locoregional recurrence rate in patients with DCIS treated with BCT is similar to that in patients with early-stage invasive breast cancer treated with BCT, but time to locoregional recurrence is significantly longer in patients with DCIS. In patients with DCIS treated with BCT, intense surveillance for locoregional recurrence needs to be maintained for the patient's lifetime. |
| doi_str_mv | 10.1007/s10434-000-0656-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72334368</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72334368</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-a3bb57817643719cd7a429187df599b3658fa613e0c765901d8c76b7cfbc0ca43</originalsourceid><addsrcrecordid>eNp1kVtLw0AQhRdRrFZ_gC8SFHxbncneEt-kXioUfNHnZbPd1JRc6m4i5N-7pQVB8GkOw3cOwxxCLhBuEUDdBQTOOAUAClJIOh6QExRxw2WGh1GDzGieSjEhpyGsAVAxEMdkggiMpzw9IfPHwfamTqzxtmq7xtCqpaHqh_uk7toV7Z1vEu_CUPch6cqk8M6EntquDc5_V-0q6T-dN5vxjByVpg7ufD-n5OP56X02p4u3l9fZw4JalmFPDSsKoTJUkjOFuV0qw9McM7UsRZ4XTIqsNBKZA6ukyAGXWRSFsmVhwRrOpuRml7vx3dfgQq-bKlhX16Z13RC0ShnjTGYRvP4DrrvBt_E2nXIUCkWebqmrf6lUMcEQRIRwB1nfheBdqTe-aowfNYLeNqF3TejYhN42ocfoudwHD0Xjlr-O_evZD9p_glU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227353105</pqid></control><display><type>article</type><title>Ductal carcinoma-in-situ: long-term results of breast-conserving therapy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mirza, N Q ; Vlastos, G ; Meric, F ; Sahin, A A ; Singletary, S E ; Newman, L A ; Kuerer, H M ; Ames, F C ; Ross, M I ; Feig, B W ; Pollock, R E ; Buchholz, T A ; McNeese, M D ; Strom, E A ; Hortobagyi, G N ; Hunt, K K</creator><creatorcontrib>Mirza, N Q ; Vlastos, G ; Meric, F ; Sahin, A A ; Singletary, S E ; Newman, L A ; Kuerer, H M ; Ames, F C ; Ross, M I ; Feig, B W ; Pollock, R E ; Buchholz, T A ; McNeese, M D ; Strom, E A ; Hortobagyi, G N ; Hunt, K K</creatorcontrib><description>The role of breast-conserving therapy (BCT) in the management of ductal carcinoma-in-situ (DCIS) is controversial because of reported high recurrence rates. We reviewed our experience to determine whether the rate and pattern of locoregional recurrence after BCT were similar in patients with DCIS and patients with early-stage (T1) invasive breast tumors and whether local recurrence affected survival.
Between 1973 and 1994, 87 patients with DCIS alone, 22 patients with DCIS with microinvasion (DCIS-M), and 646 patients with invasive breast cancer 2 cm or smaller in diameter were treated with BCT (wide local excision with radiotherapy) at The University of Texas M. D. Anderson Cancer Center. Survival was calculated by the Kaplan-Meier method. The median follow-up times were 11 years for patients with DCIS alone, 12 years for patients with DCIS-M, and 8 years for patients with invasive breast cancer.
Eleven (13%) of 87 patients with DCIS and 5 (23%) of 22 patients with DCIS-M had developed locoregional recurrences at follow-up. Two patients with DCIS with locoregional recurrence died of breast cancer. Of the 646 patients with invasive breast cancer, 56 (9%) had a locoregional recurrence, and 16 (2%) died of breast cancer. The median time to locoregional recurrence was significantly longer in patients with DCIS or DCIS-M (9-10 years) than patients with invasive tumors (5 years).
DCIS is a favorable disease with an excellent long-term survival. The locoregional recurrence rate in patients with DCIS treated with BCT is similar to that in patients with early-stage invasive breast cancer treated with BCT, but time to locoregional recurrence is significantly longer in patients with DCIS. In patients with DCIS treated with BCT, intense surveillance for locoregional recurrence needs to be maintained for the patient's lifetime.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1007/s10434-000-0656-y</identifier><identifier>PMID: 11034242</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Adult ; Aged ; Breast cancer ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Carcinoma, Intraductal, Noninfiltrating - mortality ; Carcinoma, Intraductal, Noninfiltrating - pathology ; Carcinoma, Intraductal, Noninfiltrating - secondary ; Carcinoma, Intraductal, Noninfiltrating - therapy ; Chemotherapy, Adjuvant ; Female ; Humans ; Invasiveness ; Lymphatic Metastasis ; Mastectomy ; Mastectomy, Segmental - mortality ; Medical Records ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local - prevention & control ; Radiation therapy ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Analysis ; Texas - epidemiology ; Tumors</subject><ispartof>Annals of surgical oncology, 2000-10, Vol.7 (9), p.656-664</ispartof><rights>The Society of Surgical Oncology, Inc. 2000</rights><rights>The Society of Surgical Oncology, Inc. 2000.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-a3bb57817643719cd7a429187df599b3658fa613e0c765901d8c76b7cfbc0ca43</citedby><cites>FETCH-LOGICAL-c381t-a3bb57817643719cd7a429187df599b3658fa613e0c765901d8c76b7cfbc0ca43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11034242$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mirza, N Q</creatorcontrib><creatorcontrib>Vlastos, G</creatorcontrib><creatorcontrib>Meric, F</creatorcontrib><creatorcontrib>Sahin, A A</creatorcontrib><creatorcontrib>Singletary, S E</creatorcontrib><creatorcontrib>Newman, L A</creatorcontrib><creatorcontrib>Kuerer, H M</creatorcontrib><creatorcontrib>Ames, F C</creatorcontrib><creatorcontrib>Ross, M I</creatorcontrib><creatorcontrib>Feig, B W</creatorcontrib><creatorcontrib>Pollock, R E</creatorcontrib><creatorcontrib>Buchholz, T A</creatorcontrib><creatorcontrib>McNeese, M D</creatorcontrib><creatorcontrib>Strom, E A</creatorcontrib><creatorcontrib>Hortobagyi, G N</creatorcontrib><creatorcontrib>Hunt, K K</creatorcontrib><title>Ductal carcinoma-in-situ: long-term results of breast-conserving therapy</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>The role of breast-conserving therapy (BCT) in the management of ductal carcinoma-in-situ (DCIS) is controversial because of reported high recurrence rates. We reviewed our experience to determine whether the rate and pattern of locoregional recurrence after BCT were similar in patients with DCIS and patients with early-stage (T1) invasive breast tumors and whether local recurrence affected survival.
Between 1973 and 1994, 87 patients with DCIS alone, 22 patients with DCIS with microinvasion (DCIS-M), and 646 patients with invasive breast cancer 2 cm or smaller in diameter were treated with BCT (wide local excision with radiotherapy) at The University of Texas M. D. Anderson Cancer Center. Survival was calculated by the Kaplan-Meier method. The median follow-up times were 11 years for patients with DCIS alone, 12 years for patients with DCIS-M, and 8 years for patients with invasive breast cancer.
Eleven (13%) of 87 patients with DCIS and 5 (23%) of 22 patients with DCIS-M had developed locoregional recurrences at follow-up. Two patients with DCIS with locoregional recurrence died of breast cancer. Of the 646 patients with invasive breast cancer, 56 (9%) had a locoregional recurrence, and 16 (2%) died of breast cancer. The median time to locoregional recurrence was significantly longer in patients with DCIS or DCIS-M (9-10 years) than patients with invasive tumors (5 years).
DCIS is a favorable disease with an excellent long-term survival. The locoregional recurrence rate in patients with DCIS treated with BCT is similar to that in patients with early-stage invasive breast cancer treated with BCT, but time to locoregional recurrence is significantly longer in patients with DCIS. In patients with DCIS treated with BCT, intense surveillance for locoregional recurrence needs to be maintained for the patient's lifetime.</description><subject>Adult</subject><subject>Aged</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Carcinoma, Intraductal, Noninfiltrating - mortality</subject><subject>Carcinoma, Intraductal, Noninfiltrating - pathology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - secondary</subject><subject>Carcinoma, Intraductal, Noninfiltrating - therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Female</subject><subject>Humans</subject><subject>Invasiveness</subject><subject>Lymphatic Metastasis</subject><subject>Mastectomy</subject><subject>Mastectomy, Segmental - mortality</subject><subject>Medical Records</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Radiation therapy</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Texas - epidemiology</subject><subject>Tumors</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kVtLw0AQhRdRrFZ_gC8SFHxbncneEt-kXioUfNHnZbPd1JRc6m4i5N-7pQVB8GkOw3cOwxxCLhBuEUDdBQTOOAUAClJIOh6QExRxw2WGh1GDzGieSjEhpyGsAVAxEMdkggiMpzw9IfPHwfamTqzxtmq7xtCqpaHqh_uk7toV7Z1vEu_CUPch6cqk8M6EntquDc5_V-0q6T-dN5vxjByVpg7ufD-n5OP56X02p4u3l9fZw4JalmFPDSsKoTJUkjOFuV0qw9McM7UsRZ4XTIqsNBKZA6ukyAGXWRSFsmVhwRrOpuRml7vx3dfgQq-bKlhX16Z13RC0ShnjTGYRvP4DrrvBt_E2nXIUCkWebqmrf6lUMcEQRIRwB1nfheBdqTe-aowfNYLeNqF3TejYhN42ocfoudwHD0Xjlr-O_evZD9p_glU</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>Mirza, N Q</creator><creator>Vlastos, G</creator><creator>Meric, F</creator><creator>Sahin, A A</creator><creator>Singletary, S E</creator><creator>Newman, L A</creator><creator>Kuerer, H M</creator><creator>Ames, F C</creator><creator>Ross, M I</creator><creator>Feig, B W</creator><creator>Pollock, R E</creator><creator>Buchholz, T A</creator><creator>McNeese, M D</creator><creator>Strom, E A</creator><creator>Hortobagyi, G N</creator><creator>Hunt, K K</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20001001</creationdate><title>Ductal carcinoma-in-situ: long-term results of breast-conserving therapy</title><author>Mirza, N Q ; Vlastos, G ; Meric, F ; Sahin, A A ; Singletary, S E ; Newman, L A ; Kuerer, H M ; Ames, F C ; Ross, M I ; Feig, B W ; Pollock, R E ; Buchholz, T A ; McNeese, M D ; Strom, E A ; Hortobagyi, G N ; Hunt, K K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-a3bb57817643719cd7a429187df599b3658fa613e0c765901d8c76b7cfbc0ca43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Carcinoma, Intraductal, Noninfiltrating - mortality</topic><topic>Carcinoma, Intraductal, Noninfiltrating - pathology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - secondary</topic><topic>Carcinoma, Intraductal, Noninfiltrating - therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Female</topic><topic>Humans</topic><topic>Invasiveness</topic><topic>Lymphatic Metastasis</topic><topic>Mastectomy</topic><topic>Mastectomy, Segmental - mortality</topic><topic>Medical Records</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Radiation therapy</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Texas - epidemiology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mirza, N Q</creatorcontrib><creatorcontrib>Vlastos, G</creatorcontrib><creatorcontrib>Meric, F</creatorcontrib><creatorcontrib>Sahin, A A</creatorcontrib><creatorcontrib>Singletary, S E</creatorcontrib><creatorcontrib>Newman, L A</creatorcontrib><creatorcontrib>Kuerer, H M</creatorcontrib><creatorcontrib>Ames, F C</creatorcontrib><creatorcontrib>Ross, M I</creatorcontrib><creatorcontrib>Feig, B W</creatorcontrib><creatorcontrib>Pollock, R E</creatorcontrib><creatorcontrib>Buchholz, T A</creatorcontrib><creatorcontrib>McNeese, M D</creatorcontrib><creatorcontrib>Strom, E A</creatorcontrib><creatorcontrib>Hortobagyi, G N</creatorcontrib><creatorcontrib>Hunt, K K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mirza, N Q</au><au>Vlastos, G</au><au>Meric, F</au><au>Sahin, A A</au><au>Singletary, S E</au><au>Newman, L A</au><au>Kuerer, H M</au><au>Ames, F C</au><au>Ross, M I</au><au>Feig, B W</au><au>Pollock, R E</au><au>Buchholz, T A</au><au>McNeese, M D</au><au>Strom, E A</au><au>Hortobagyi, G N</au><au>Hunt, K K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ductal carcinoma-in-situ: long-term results of breast-conserving therapy</atitle><jtitle>Annals of surgical oncology</jtitle><addtitle>Ann Surg Oncol</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>7</volume><issue>9</issue><spage>656</spage><epage>664</epage><pages>656-664</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>The role of breast-conserving therapy (BCT) in the management of ductal carcinoma-in-situ (DCIS) is controversial because of reported high recurrence rates. We reviewed our experience to determine whether the rate and pattern of locoregional recurrence after BCT were similar in patients with DCIS and patients with early-stage (T1) invasive breast tumors and whether local recurrence affected survival.
Between 1973 and 1994, 87 patients with DCIS alone, 22 patients with DCIS with microinvasion (DCIS-M), and 646 patients with invasive breast cancer 2 cm or smaller in diameter were treated with BCT (wide local excision with radiotherapy) at The University of Texas M. D. Anderson Cancer Center. Survival was calculated by the Kaplan-Meier method. The median follow-up times were 11 years for patients with DCIS alone, 12 years for patients with DCIS-M, and 8 years for patients with invasive breast cancer.
Eleven (13%) of 87 patients with DCIS and 5 (23%) of 22 patients with DCIS-M had developed locoregional recurrences at follow-up. Two patients with DCIS with locoregional recurrence died of breast cancer. Of the 646 patients with invasive breast cancer, 56 (9%) had a locoregional recurrence, and 16 (2%) died of breast cancer. The median time to locoregional recurrence was significantly longer in patients with DCIS or DCIS-M (9-10 years) than patients with invasive tumors (5 years).
DCIS is a favorable disease with an excellent long-term survival. The locoregional recurrence rate in patients with DCIS treated with BCT is similar to that in patients with early-stage invasive breast cancer treated with BCT, but time to locoregional recurrence is significantly longer in patients with DCIS. In patients with DCIS treated with BCT, intense surveillance for locoregional recurrence needs to be maintained for the patient's lifetime.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>11034242</pmid><doi>10.1007/s10434-000-0656-y</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2000-10, Vol.7 (9), p.656-664 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72334368 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Breast cancer Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Carcinoma, Intraductal, Noninfiltrating - mortality Carcinoma, Intraductal, Noninfiltrating - pathology Carcinoma, Intraductal, Noninfiltrating - secondary Carcinoma, Intraductal, Noninfiltrating - therapy Chemotherapy, Adjuvant Female Humans Invasiveness Lymphatic Metastasis Mastectomy Mastectomy, Segmental - mortality Medical Records Middle Aged Neoplasm Invasiveness Neoplasm Recurrence, Local - prevention & control Radiation therapy Radiotherapy, Adjuvant Retrospective Studies Survival Analysis Texas - epidemiology Tumors |
| title | Ductal carcinoma-in-situ: long-term results of breast-conserving therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T03%3A17%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ductal%20carcinoma-in-situ:%20long-term%20results%20of%20breast-conserving%20therapy&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Mirza,%20N%20Q&rft.date=2000-10-01&rft.volume=7&rft.issue=9&rft.spage=656&rft.epage=664&rft.pages=656-664&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1007/s10434-000-0656-y&rft_dat=%3Cproquest_cross%3E72334368%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227353105&rft_id=info:pmid/11034242&rfr_iscdi=true |